peter kolchinsky net worth

Ben Ford was born and raised in Ames, Iowa. Sign up here. Peter Kolchinsky overall profits are growing on a daily basis, and he is becoming more popular on the sidelines. Peter Kolchinsky owns about 1,311,247 units of Mineralys. Harvard Divinity School and began doctoral work in Buddhist studies at the University of California, Berkeley. He studied philosophy at Oregon State University and then earned a law degree from the University of Oklahoma. Kolchinsky Peter Ownership Network Ownership Network List of Kolchinsky Peter Name Position Linked company No Data Ownership Network Relation of Kolchinsky Peter Kolchinsky Peter Mailing Address Above is the net worth, insider trading, and ownership report for Kolchinsky Peter. Refer a Friend and Earn One Month of Free Membership. Peter Kolchinsky is 43, he's been the Independent Director of Wave Life Sciences since 2015. Current Endpoints readerscan visit their reader profileto add Endpoints Weekly. $5M . Peter Kolchinsky / Published in City Journal / February 24, 2020 "Some health economists, such as those at the Institute for Clinical and Economic Review (ICER), believe that they can tell us the right price to pay for each new medicine that the FDA approves. The most active traders at the company are (LogOut/ Peter Kolchinsky is a biotechnology investor and a scientist. Nexus is expected to participate in substantially all investments in private companies made by RA Capital alongside its main, longstanding fund, RA Capital Healthcare Fund L.P. The current estimated net worth of Dyne Therapeutics, Inc's Peter Kolchinsky is estimated to be about $2.7B . Change), You are commenting using your Twitter account. On average, Peter trades about 366,737 units every 19 days since 2014. This . $20M on February 16, 2023. So they invited their close friends Keri and Ben up for what they, Keri and Ben, long-time city dwellers, were, new dream and a substantial life-style change, One of my favorite paintings is from the Blue Horses, , and, of course, horses were what brought the couple to Woodstock. Source: https://www.sec.gov/Archives/edgar/data/1818794/000119312521116286/d937458ddef14a.htm. . All Rights Reserved. He currently manages a fund that invests in healthcare and biotechnology companies. Peter's mailing address filed with the SEC is C/O RA CAPITAL MANAGEMENT, L.P., 200 BERKELEY STREET, 18TH FLOOR, BOSTON, MA, 02116. Things here have been busy; were working hard to get the inn ready for our June 2010 grand opening. Anna and Peter originally hoped to find a vacation home that was big enough to share with friends and family and looked at the inn more out of curiosity than with any real intention to purchase it. A biotech analyst bets Novavax has the best data. $3.3K . foundation had somehow failed patients by allowing Vertex to price its drugs so high that a 10 percent royalty could be worth so much. I don't believe that temperature plays a role in the spread of Covid-19. Arab Health 2023? Save my name, email, and website in this browser for the next time I comment. Endpoints News Top biotech investor Peter Kolchinsky tees up a new SPAC 3 days after a $300M raise for radiopharmaceuticals play News Dec 9, 2020 Endpoints News RA Capital backs Oxford spinout PepGen with a $45M Series A, seeking to treat Duchenne and other similar diseases January 3, 2023 Feb 10th, Ed. What an undertaking! His wife, Nora Flor, said she and her sister made calls to at least 30 centers across the US looking for the drug. Peter Kolchinsky's largest purchase order was 3,178,476 units , worth over Above is the net worth, insider trading, and ownership report for Kolchinsky Peter. In the interim, they plan to invite, Were not in a rush, Anna explained, and want to take some time to get to know the. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. He co-founded and runs the Boston-based investment firm RA Capital Management; writes and teaches about biomedical entrepreneurship and its potential to transform global health; serves on the boards of several public and private drug development companies; and lives in Massachusetts with his historian/equestrian wife, strong-willed children, and reasonably well-trained dog. The estimated Net Worth of Peter Kolchinsky is at least $105 Milion dollars as of 23 June 2020. New to Endpoints? Kolchinsky who spoke to senior editor Shiv Aroor as part . Well be posting shots of the different projects around the inn in the coming weeks, but first we thought you might like to know a little bit about us. Wishing you all the best of luck in your new endeavor. These things have helped him get to where he is now one of the richest people on Earth. Dr. Kolchinsky is a founder and Managing Partner of RA Capital Management, L.P., a multi-stage investment manager which is dedicated to evidence-based investing in healthcare and life science companies that are developing drugs, medical devices, and diagnostics, where he has worked since 2001. Please note GuruFocus will not track the insiders transaction performance if he/she does not have buying transactions. Required fields are marked *. Stock quotes provided by InterActive Data. The RA Capital Nexus Fund closed at just over $300 million, they said in a statement. Add it to the rest of the money and their private deal capacity jumps to $1 billion, with $2.5 billion under management. I am on Oahu until Friday, so please feel free to also contact me directly in order to discuss Anna and Peter discovered Woodstock through Annas participation at the GMHA dressage events. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Welcome to the official Blue Horse Inn blog! Your email address will not be published. The Great American Drug Deal examines the healthcare landscape through the lens of this contract, including the government's role in inventing drugs, direct-to-consumer advertising, the opioid crisis, the price-jacking of old drugs, and the impact on America of lower drug costs in other countries. Peter Kolchinsky is a founder, Portfolio Manager, and Managing Director at RA Capital Management, LLC, a multi-stage investment manager dedicated to evidence-based investing in healthcare and. March 31, 2020. Words cant bring Christina Aguilera down but frown lines can. The current estimated net worth of Mineralys Therapeutics, Inc's Director, Peter Kolchinsky, is estimated to be about $2.92B . Coming from diverse backgrounds and interests, the foursome sees Woodstock as a venue for exploring their particular passions. Please note GuruFocus will not track the insiders transaction performance if he/she does not have buying transactions. The higher rates are proposed to kick in on April 1. In the interim, they plan to invite local folks in to see the changes, try out some wines, and make new friends. Merz has previously enlisted singer-songwriters Joe Jonas and Teyana Taylor, 33 and 31 years old respectively, who tout the anti-wrinkle injection as a solution for frown lines without any unnecessary ingredients., Bioscience & Technology Business CenterThe University of KansasLawrence, Kansas. Peter Kolchinsky's largest purchase order was 2,805,045 units , worth over Hedge Fund Net Worth $4.93B Peter Kolchinsky manages more assets than 43% of other Hedge Fund Managers Average Return +0.32% Since Last Filing Last 12 Months 3 Years (Annualized) Portfolio Breakdown by Sector Portfolio Breakdown 97.31% Healthcare 1.12% Services 0.78% Technology 0.51% Financial RA Capital Management Portfolio Activity Company Name As the Independent Director of Wave Life Sciences, the total compensation of Peter Kolchinsky at Wave Life Sciences is $151,598. Come and visit me at the Pacific Water Conference, booth 520! The foursome plans to open for guests in the late spring of 2010. The biopharmaceutical industry will be able to make a Covid-19 vaccineprobably a few of themusing various existing vaccine technologies. Peter Kolchinsky owns about 10,916,567 units of Solid Biosciences Inc common stock. Peter Kolchinsky, Ph.D. Peter Kolchinsky, PhD '01, is a founder, Portfolio Manager, and Managing Director at RA Capital Management, LLC, a multi-stage investment manager dedicated to evidence-based investing in healthcare and life sciences. and bought an estimated value of $190.71M worth of shares. Please note the magic link is So they invited their close friends Keri and Ben up for what they expected to be a reality check. In total, Peter Kolchinsky has made about 1 transaction recently at Dyne Therapeutics, Inc. Enjoy a 7-Day Free Trial Thru Mar 12, 2023! Currently GuruFocus does not have mailing address information for Kolchinsky Peter. Please note this link is one-time use only and is valid for only 24 hours. Momentum Activist Targets Dividend Yield Microcap with Revenue NCAV Screen Net Net Working Capital Negative Enterprise Value Piotroski Score ROIC Screen Short Volume Ratio High . Jonathan McNeill who sold 10,000 units worth $12.54M on September 23, 2020. Other family members and associates include Alexander Kolchinsky, Evelina Kolchinsky, Anna Kolchinsky, Joseph Kolchinsky and Joseph Kolchinsky. The Voluntary Scheme for Branded Medicines Pricing and Access is the second option, and typically has lower rates and is negotiated between the government and pharmas. They know that 3 Church Street is part of Woodstocks history and hope to create a place where not only guests but also the community will feel welcome. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. out how to maintain the house themselves, from the roof to the, Anna and Keri hope their husbands dont electroc, can be found busily working at The Blue Horse Inn most weekends. Dyne Therapeutics, Inc's most recent insider trade came on January 23, 2023 by December 22nd, 2014. . Peter Kolchinsky owns over 4,000,000 units of Wave Life Sciences stock worth over $46,860,585 and over the last 8 years he sold WVE stock worth over $58,095,632. . "Stay tuned for more covid and science explainers. Peter Kolchinsky's largest purchase order was 2,206,685 units , worth over The oldest executive at Wave Life Sciences Ltd. is KojiMiura, 71, who is the Independent Director. Peter Kolchinsky: It has infected people in different parts of the world. No. Above is the net worth, insider trading, and ownership report for Kolchinsky Peter. A quarters-long flurry of layoffs has caused thousands of workers in life sciences to go hunting for their next position sooner than expected, and the latest wave could make it more difficult to get new offers in hand in short order. The current estimated net worth of Dyne Therapeutics, Inc's Peter Kolchinsky is estimated to be about $2.88B . Stock quotes provided by InterActive Data. Peter Kolchinsky owns over 4,000,000 units of Wave Life Sciences stock worth over $38,029,167 and over the last 9 years he sold WVE stock worth over $58,095,632. Right now, he is the most trending person in social media. Bens got me beat so far by three perch and a bass and Im trying to catch up. He co-founded and runs the Boston-based investment firm RA Capital Management, writes and teaches about biomedical entrepreneurship and its potential to transform global health, serves on the boards of several public and private drug development companies, and has served on the Board of Global Science and Technology for the National . GuruFocus.com is not operated by a broker or a dealer. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. America is rightfully outraged when patients cant afford the medicines they need. Dr. Kolchinsky's firm held 7.3 million Ascendis Pharma A/S (NASDAQ:ASND) shares in Q3, which were worth $1.17 billion and made up for 16.31% of its portfolio. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. Integrating digital therapeutics early in the asset development process will allow for gathering of clinical data to drive a clearer value proposition that maximizes the potential of both products